UNSPSC 51383706: Lobuprofen hydrochloride

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C25H33ClN2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D5BE0IJ3GR, chemically known as benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-, 2-(4-(3-chlorophenyl)-1-piperazinyl)ethyl ester, hydrochloride (1:1), but more generally known as lobuprofen hydrochloride, which bears US NIH Compound Identifier 65842.

European Medicines Agency schedules lobuprofen hydrochloride or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08545MIG. Most nations, for tariff purposes, schedule lobuprofen hydrochloride under HS 29335995. SMILES: CC(C)CC1CCC(CC1)C(C)C(=O)OCCN2CCN(CC2)C3CCCC(C3)CL.CL.

UNSPSC 51383706 Lobuprofen hydrochloride is a Commodity code that does not match the work actually being solicited under it in recent state and local procurement. The three recent opportunities posted under this code involve naloxone and drug deactivation systems, a Texas Health and Human Services direct-to-manufacturer prescription program, and a multistate cooperative purchasing agreement for generic pharmaceuticals and OTC products — none of which involve lobuprofen hydrochloride specifically. The mismatch suggests either a systematic tagging error across multiple jurisdictions or that the code is being used as a general container for pharmaceutical procurement without product-specific relevance. State and local governments soliciting under this code designation are purchasing broad pharmaceutical product lines through competitive bidding, cooperative purchasing vehicles, and exploratory requests for information, but the code's nominal product name does not align with the actual scope of work being conducted.

The issuing bodies include county health departments (Seminole County, Florida), state health and human services commissions (Texas HHS Commission), and multistate cooperative purchasing alliances (Minnesota Multistate Cooperative Purchasing Alliance serving Minnesota, Oregon, and other participants). Geographic activity spans Florida, Texas, and the upper Midwest, with the Minnesota MMCAP opportunity representing the broadest jurisdictional reach. Representative recent opportunities include Seminole County's IFB 60459723LAS for 1,900 units of naloxone and 800 safe drug deactivation systems with quarterly deliveries and a response deadline of July 26, 2023; Texas HHS Commission's RFI HHS0017013 posted April 3, 2026, exploring direct-to-manufacturer prescription programs; and Minnesota MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 deadline and a two-year initial term effective July 1, 2026. Vendors pursuing this code should recognize that the code designation does not reliably predict commodity scope and should verify actual product requirements in each solicitation.